Healthcare -
Biotechnology - NASDAQ - US
$ 8.63
-0.918 %
$ 64.8 M
Market Cap
-1.29
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
Assembly Biosciences, Inc.
| Current Assets | 116 M |
| Cash & Short-Term Investments | 112 M |
| Receivables | 0 |
| Other Current Assets | 3.42 M |
| Non-Current Assets | 3.66 M |
| Long-Term Investments | 0 |
| PP&E | 3.35 M |
| Other Non-Current Assets | 312 K |
| Current Liabilities | 47.8 M |
| Accounts Payable | 585 K |
| Short-Term Debt | 461 K |
| Other Current Liabilities | 46.8 M |
| Non-Current Liabilities | 38 M |
| Long-Term Debt | 2.63 M |
| Other Non-Current Liabilities | 35.4 M |
EFFICIENCY
Earnings Waterfall
Assembly Biosciences, Inc.
| Revenue | 28.5 M |
| Cost Of Revenue | 0 |
| Gross Profit | 28.5 M |
| Operating Expenses | 73.9 M |
| Operating Income | -45.4 M |
| Other Expenses | -5.24 M |
| Net Income | -40.2 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Assembly Biosciences, Inc.
| Net Income | -40.2 M |
| Depreciation & Amortization | 129 K |
| Capital Expenditures | -28 K |
| Stock-Based Compensation | 3.12 M |
| Change in Working Capital | -11.9 M |
| Others | -14.4 M |
| Free Cash Flow | -51.1 M |
Wall Street Analysts Price Targets
Assembly Biosciences, Inc.
Wall Street analysts predict an average 1-year price target for ASMB of $35.5 , with forecasts ranging from
a
low of
$35 to a high of $36 .
ASMB Lowest Price Target
Wall Street Target
35 USD
305.56%
ASMB Average Price Target
Wall Street Target
35.5 USD
311.36%
ASMB Highest Price Target
Wall Street Target
36 USD
317.15%
4. DIVIDEND
ANALYSIS
ASMB does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Assembly Biosciences, Inc.
Sold
0-3 MONTHS
7.21 K USD 3
3-6 MONTHS
652 USD 1
6-9 MONTHS
30.4 K USD 2
9-12 MONTHS
78.6 K USD 4
Bought
0 USD 0
0-3 MONTHS
20.5 M USD 3
3-6 MONTHS
146 K USD 1
6-9 MONTHS
3.16 M USD 2
9-12 MONTHS
7. News
Assembly Biosciences (ASMB) Upgraded to Buy: What Does It Mean for the Stock?
Assembly Biosciences (ASMB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
- 3 weeks ago
Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights
– Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline –
globenewswire.com
- 1 month ago
Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
– Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 – – Biomarker of ABI-6250 target engagement, serum bile acids, will be assessed in addition to safety and pharmacokinetic measures – SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1a trial of ABI-6250, the company's orally bioavailable, small molecule hepatitis delta virus (HDV) entry inhibitor candidate.
globenewswire.com
- 1 month ago
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes
– ABI-1179 was well-tolerated, with a half-life of approximately four days and high exposure across the dose range evaluated supporting the potential for once-weekly oral administration at a low dose –
globenewswire.com
- 1 month ago
Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B
– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed –
globenewswire.com
- 3 months ago
Is Assembly Biosciences (ASMB) Stock Outpacing Its Medical Peers This Year?
Here is how Assembly Biosciences (ASMB) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
zacks.com
- 7 months ago
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented –
globenewswire.com
- 9 months ago
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366
– Phase 1a study portion of single ascending dosing in healthy participants will inform the development of ABI-5366 with interim data expected in Q3 2024 –
globenewswire.com
- 10 months ago
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024
-- Preclinical data from both ABI-5366 and ABI-1179, Assembly Bio's long-acting helicase-primase inhibitor candidates targeting recurrent genital herpes, featured in poster and oral presentations at the International Herpesvirus Workshop -- -- Poster accepted for presentation at EASL Congress™ 2024 highlights preclinical profile of ABI-6250, a novel, small molecule orally-bioavailable entry inhibitor candidate for hepatitis D --
globenewswire.com
- 10 months ago
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results and recent highlights for the first quarter ended March 31, 2024.
globenewswire.com
- 11 months ago
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results and recent highlights for the fourth quarter and year ended December 31, 2023.
globenewswire.com
- 1 year ago
Assembly Biosciences Announces Effective Date of Reverse Stock Split
– Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 –
globenewswire.com
- 1 year ago
8. Profile
Summary
Assembly Biosciences, Inc. ASMB
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 64.8 M
Dividend Yield
0.00%
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Contact
331 Oyster Point Boulevard, South San Francisco, CA, 94080
https://www.assemblybio.com
IPO
Date
Dec. 17, 2010
Employees
73
Officers
Dr. William E. Delaney IV, Ph.D.
Chief Scientific Officer
Ms. Jeanette M. Bjorkquist
Executive Director of Accounting & Treasury
Ms. Jennifer A. Troia MHROD, SHRM-SCP, SPHR
Chief Human Resources Officer
Dr. Anuj Gaggar M.D., Ph.D.
Chief Medical Officer
Amy Figueroa C.F.A.
Investor Relations Consultant
Mr. Jason A. Okazaki J.D.
Chief Executive Officer, President & Director
Dr. Nicole S. White Ph.D.
Chief Manufacturing Officer
Mr. Shannon Ryan
Senior Vice President of Investor Relations, Corporate Affairs & Alliance Management
Mr. Thomas E. Rollins
Executive Officer